

MHRA approves nogapendekin alfa inbakicept to treat adult patients with non-muscle invasive bladder cancer

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 July 2025, approved nogapendekin alfa inbakicept (Anktiva) for adults with BCG-unresponsive non-muscle invasive bladder cancer, where the disease re...